ClinicalTrials.gg
CompletedNCT05692739Updated Mar 5, 2026

Clinical Trial To Determine The Effectiveness And Safety Of Topical Insulin In Dry Eye

A Phase 4 interventional study of Insulin and Cyclosporins in Dry Eye and Insulin, sponsored by Barbara Burgos Blasco. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Barbara Burgos Blasco · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Dry Eye Syndromes with a site in Spain — 3 open to participants now, 4 under way, none of them phase 3. Dry Eye Syndromes · Spain.

Enrollment
10th of 41
116 · median 60
Started
2022
with 4 others
Phase 4
5 of 44
2 open now
Registered
28th of 44
by date
Lead sponsor
2 of 44
Barbara Burgos Blasco

Among the 44 studies in Dry Eye Syndromes with a site in Spain, this one is the 10th largest by enrollment of the 41 interventional ones that give a count, is one of 5 that started in 2022, is one of 5 in phase 4, and was the 28th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

3 of the 44 studies in Dry Eye Syndromes with a site in Spain are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Dry Eye Syndromes with a site in Spain, or all of them as a file.
02

Study summary

This is a parallel randomized controlled trial for the treatment of dry eye disease. The main objective is to investigate the efficacy and safety of the use of insulin eye drops in the control of moderate-severe dry eye disease. Topical insulin drops will be compared to the current gold standard treatment, cyclosporin and placebo (artificial tears).

Read the detailed description

Patients will be recruited in Madrid. Patients with dry eye disease and no topical treatment other than artificial tears will be identified through the Ophthalmology clinic. They will be directly referred to a physician who is participating in this study.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients older than 18 years
  • Dry eye disease diagnosis
  • Treatment with artificial tears or hyaluronic acid gels for at least 3 months
  • Signed by the patient
  • Staining equal to or greater than Oxford II

Exclusion criteria

Exclusion Criteria:

  • Under 18 years old
  • Corneal staining under Oxford II
  • Treatment for dry eye disease other than artificial tears or hyaluronic acid gels
  • Severe dry eye disease that requires immediate treatment
  • Eye surgery in the last 6 months
  • Other concomitant corneal pathology, eyelid malpositions, nasolacrimal drainage abnormalities, blinking alterations
  • Contact lenses
  • Other treatment besides artificial tears or hyaluronic acid gels
  • Visual acuity less than 0.1
  • Allergy or intolerance to any of the components included in the study
  • Modifications in systemic treatment
  • Pregnancy or lactation
  • Women of childbearing age who do not use a highly effective method
  • History of alcohol or drug abuse
  • Participation in another clinical trial in the last 30 days
  • Systemic pathology (cardiopulmonary pathology, connective tissue disorders, neurological or psychiatric pathology) or baseline situation of the patient that does not allow the examination (such as mental or psychomotor retardation)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    Insulin

    Topical insulin 1UI/ml 4 times a day

    Drug: Insulin

  • Active comparator
    Cyclosporin

    Cyclosporin 0,05% every 12 hours

    Drug: Cyclosporins

  • Placebo comparator
    Artificial tears

    Artificial tears 4 times a day

    Drug: Artificial tears

Interventions

  • see arm description

  • see arm description

  • DrugArtificial tears

    see arm description

06

What researchers measure

Primary outcomes

  1. Change of corneal staining from baseline to 6 months after treatment

    Corneal staining will be evaluated on the slit-lamp and on slit-lamp images (masked evaluator)

    Time frame: From baseline to 6 months after treatment

Secondary outcomes

  1. Changes in dry eye symptoms from baseline to 6 months after treatment time

    Dry eye symptoms will be evaluated using OSDI

    Time frame: From baseline to 6 months after treatment

  2. Changes in esthesiometry from baseline to 6 months after treatment time

    Esthesiometry will be evaluated using an esthesiometer

    Time frame: From baseline to 6 months after treatment

  3. Changes in tear rupture time from baseline to 6 months after treatment time

    Tear rupture time will be evaluated using the Keratograph (Oculus)

    Time frame: From baseline to 6 months after treatment

07

Study locations

1 site
  • Hospital Clinico San Carlos
    Madrid, Spain
08

References and documents

Publications

  • Diaz-Valle D, Burgos-Blasco B, Rego-Lorca D, Puebla-Garcia V, Perez-Garcia P, Benitez-Del-Castillo JM, Herrero-Vanrell R, Vicario-de-la-Torre M, Gegundez-Fernandez JA. Comparison of the efficacy of topical insulin with autologous serum eye drops in persistent epithelial defects of the cornea. Acta Ophthalmol. 2022 Jun;100(4):e912-e919. doi: 10.1111/aos.14997. Epub 2021 Aug 18. PubMed 34407296 ↗
  • Diaz-Valle D, Burgos-Blasco B, Gegundez-Fernandez JA, Garcia-Caride S, Puebla-Garcia V, Pena-Urbina P, Benitez-Del-Castillo JM. Topical insulin for refractory persistent corneal epithelial defects. Eur J Ophthalmol. 2021 Sep;31(5):2280-2286. doi: 10.1177/1120672120958307. Epub 2020 Sep 21. PubMed 32951459 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Nov 2025, 36 months.

Of 85 non-industry phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's 36 months is above that.

Counting every sponsor, half of 113 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2023
First posted
Jan 20, 2023
StartActual
Oct 19, 2022
Primary completionActual
Nov 5, 2025
CompletionActual
Nov 5, 2025
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05692739
Lead sponsor
Barbara Burgos Blasco
Responsible party
Barbara Burgos Blasco (Ophthalmologist, Hospital San Carlos, Madrid) — Sponsor-investigator
First posted
Jan 20, 2023
Start date
Oct 19, 2022
Primary completion
Nov 5, 2025
Completion
Nov 5, 2025
Last update
Mar 5, 2026

Study contacts

Barbara Burgos Blasco, MD, PhD
principal investigator · Hospital Clinico San Carlos

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin

Start the discussion